These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29885068)

  • 41. Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28-0126 in healthy male subjects.
    Kim S; Chung H; Lee S; Cho SH; Cho HJ; Kim SH; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2017 Jun; 83(6):1205-1215. PubMed ID: 28002882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
    Geven C; van Lier D; Blet A; Peelen R; Ten Elzen B; Mebazaa A; Kox M; Pickkers P
    Br J Clin Pharmacol; 2018 Sep; 84(9):2129-2141. PubMed ID: 29856470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC; Shaughnessy L; Cummings D; Pezzullo JC; Wargin W; Gagnon R; Oliva J; Kosutic G
    J Clin Pharmacol; 2008 Feb; 48(2):193-202. PubMed ID: 18199894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers.
    Anand R; Seiberling M; Kamtchoua T; Pokorny R
    Clin Pharmacokinet; 2007; 46(4):351-8. PubMed ID: 17375985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Eur J Pharm Sci; 2017 Nov; 109():78-85. PubMed ID: 28778464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.
    Steudel W; Dingmann C; Zhang YL; Bendrick-Peart J; Clavijo C; Shulze J; Betts R; Christians U
    J Clin Pharmacol; 2011 Jan; 51(1):29-39. PubMed ID: 20305057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator AZD5423 after Inhalation in Healthy Volunteers.
    Werkström V; Prothon S; Ekholm E; Jorup C; Edsbäcker S
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):574-581. PubMed ID: 27214145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects.
    Eckburg PB; Lister T; Walpole S; Keutzer T; Utley L; Tomayko J; Kopp E; Farinola N; Coleman S
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early clinical experience with the novel NMDA receptor antagonist CNS 5161.
    Walters MR; Bradford AP; Fischer J; Lees KR
    Br J Clin Pharmacol; 2002 Mar; 53(3):305-11. PubMed ID: 11874394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
    Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
    Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
    Wong YN; Simcoe D; Hartman LN; Laughton WB; King SP; McCormick GC; Grebow PE
    J Clin Pharmacol; 1999 Jan; 39(1):30-40. PubMed ID: 9987698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
    Ward CL; Jamieson V; Nabata T; Sharpe J; Dozono K; Suto F; Hashimoto Y; Gussak I
    Clin Ther; 2016 May; 38(5):1109-21. PubMed ID: 27001444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.
    Kersemaekers WM; van Iersel T; Nassander U; O'Mara E; Waskin H; Caceres M; van Iersel ML
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1246-51. PubMed ID: 25512407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
    Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
    Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
    Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
    Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.